Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 88 of 580 for:    reduced glutathione

Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03172975
Recruitment Status : Recruiting
First Posted : June 1, 2017
Last Update Posted : July 18, 2018
Sponsor:
Collaborators:
George Washington University
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Maria Elena Bottazzi PhD, Baylor College of Medicine

Brief Summary:
This study evaluates the efficacy, safety and immunogenicity of different formulations of the Na-GST-1 hookworm vaccine using a controlled human hookworm infection model in healthy, hookworm-naive adults.

Condition or disease Intervention/treatment Phase
Hookworm Infections Biological: Na-GST-1/Alhydrogel Biological: Na-GST-1/Alhydrogel + CPG 10104 Biological: Na-GST-1/Alhydrogel + GLA-AF Biological: Placebo Drug: Albendazole Other: Necator americanus Larval Inoculum Phase 2

Detailed Description:

Double blind, randomized, controlled, Phase 2 clinical trial in hookworm-unexposed adults living in the metropolitan area of Washington, DC. Subjects will receive three doses of the assigned vaccine formulation, or saline placebo, delivered intramuscularly on approximately Days 0, 56, and 112.

Subjects will be challenged with 50 infectious N. americanus larvae 4 weeks after 3rd vaccination. Fecal samples will be collected weekly starting 4 weeks post-challenge. Albendazole will be administered 20 weeks post-challenge to cure infections. Subjects will be followed until 10 months after their final vaccination.

Safety of vaccination will be measured from the time of each study vaccination (Day 0) through 14 days after each study vaccination by the occurrence of solicited injection site and systemic reactogenicity events. Safety of CHHI will be measure from the time of larval application (Day 140) through the first day of treatment with albendazole (Day 280).

Unsolicited non-serious adverse events (AEs) will be collected until approximately 1 month following each study vaccination and from study Day 140 (day of CHHI) through Day 280.

New-onset chronic medical conditions and Serious Adverse Events (SAEs) will be collected from the time of the first study vaccination through approximately 10 months after the third study vaccination (final visit). Clinical laboratory evaluations for safety will be performed on venous blood collected approximately 14 days after each vaccination and CHHI.

Immunogenicity testing will include IgG antibody responses to Na-GST-1, by a qualified indirect enzyme-linked immunosorbent assay (ELISA), on serum obtained prior to each study vaccination and CHHI, and at time points after each vaccination and after CHHI (see Appendix A); the affinity of vaccine-induced antibodies against Na-GST-1 using Surface Plasmon Resonance; the functional activity of vaccine-induced antibodies via in vitro enzyme neutralization assay; antigen-specific memory B cell responses; and, the innate immune responses to each of the TLR receptor immunostimulants.

Parasitological testing will include microscopic fecal egg detection by a qualified saline flotation technique, fecal egg counts by the McMaster method, fecal PCR for hookworm DNA, and peripheral eosinophil counts.

Recruitment and enrollment into the study will occur on an ongoing basis, with each group being recruited and vaccinated in sequence.

48 subjects will be enrolled into 4 groups of 12. Subjects will be enrolled sequentially and upon enrollment will be randomized to one of the following IP assignments in a double-blind fashion:

  • Group 1 IP allocation (n=12 subjects): 12 subjects will receive 100µg Na-GST-1/Alhydrogel® delivered by IM injection in the deltoid muscle.
  • Group 2 IP allocation (n=12): 12 subjects will receive Na-GST-1/Alhydrogel® plus 500µg CpG 10104 delivered by IM injection in the deltoid muscle.
  • Group 3 IP allocation (n=12): 12 subjects will receive Na-GST-1/Alhydrogel® plus 5µg GLA-AF delivered by IM injection in the deltoid muscle.
  • Group 4 IP allocation (n=12): 12 subjects will receive sterile saline delivered by IM injection in the deltoid muscle.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Participants and investigators will be blinded to study product allocation.
Primary Purpose: Prevention
Official Title: Phase 2 Study to Assess the Safety, Efficacy and Immunogenicity of Na-GST-1/Alhydrogel Co-administered With Different Toll-Like Receptor Agonists in Hookworm- Naïve Adults
Actual Study Start Date : March 1, 2018
Estimated Primary Completion Date : August 15, 2019
Estimated Study Completion Date : December 30, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Algeldrate

Arm Intervention/treatment
Experimental: Na-GST-1/Alhydrogel
100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
Biological: Na-GST-1/Alhydrogel
Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel
Other Name: Necator americanus Glutathione-S Transferase

Drug: Albendazole
Treatment with 3 daily oral doses of 400 mg albendazole at end of study.

Other: Necator americanus Larval Inoculum
50 infectious Necator americanus larvae applied via dermal application (challenge infection).

Experimental: Na-GST-1/Alhydrogel + CPG 10104
100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
Biological: Na-GST-1/Alhydrogel + CPG 10104
Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide

Drug: Albendazole
Treatment with 3 daily oral doses of 400 mg albendazole at end of study.

Other: Necator americanus Larval Inoculum
50 infectious Necator americanus larvae applied via dermal application (challenge infection).

Experimental: Na-GST-1/Alhydrogel + GLA-AF
100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
Biological: Na-GST-1/Alhydrogel + GLA-AF
Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)

Drug: Albendazole
Treatment with 3 daily oral doses of 400 mg albendazole at end of study.

Other: Necator americanus Larval Inoculum
50 infectious Necator americanus larvae applied via dermal application (challenge infection).

Placebo Comparator: Saline Placebo
Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
Biological: Placebo
Physiological sterile saline solution

Drug: Albendazole
Treatment with 3 daily oral doses of 400 mg albendazole at end of study.

Other: Necator americanus Larval Inoculum
50 infectious Necator americanus larvae applied via dermal application (challenge infection).




Primary Outcome Measures :
  1. Detectable hookworm infection [ Time Frame: Week 20 post-CHHI ]
    Proportion of subjects with detectable hookworm eggs, at any time point, in fecal samples, as determined by microscopy using the qualified saline flotation technique

  2. Incidence of Serious Adverse Events [ Time Frame: Day 280 ]
    Frequency of study vaccine-related Serious Adverse Events from the time of the first study vaccination through approximately 10 months after the last study vaccination.

  3. Incidence of solicited injection site and systemic reactogenicity [ Time Frame: Day 14 post-vaccination ]
    Frequency of solicited injection site and systemic reactogenicity, graded by severity, on the day of each study vaccination through 14 days after each study vaccination.

  4. Incidence of solicited adverse events [ Time Frame: Day 280 ]
    Frequency of solicited adverse events, graded by severity, on the day of CHHI through study Day 280

  5. Incidence of clinical safety laboratory abnormalities [ Time Frame: Day 14 post-vaccination ]
    Frequency of clinical safety laboratory adverse events.

  6. Incidence of unsolicited adverse events [ Time Frame: Day 280 ]
    Frequency of unsolicited adverse events, graded by severity, from the time of each study vaccination through approximately 1 month after each study vaccination; and from the time of CHHI through treatment with albendazole (Day 280)

  7. Incidence of new-onset chronic medical conditions [ Time Frame: Day 280 ]
    Frequency of new-onset chronic medical conditions through approximately 10 months after the third study vaccination.

  8. Incidence of Adverse Events of Special Interest [ Time Frame: Day 280 ]
    Frequency of Adverse Events of Special Interest through approximately 10 months after the third study vaccination.


Secondary Outcome Measures :
  1. Fecal egg counts [ Time Frame: Week 5 and Week 20 post-CHHI ]
    Fecal egg counts as determined by microscopy using the McMaster method, weekly from Weeks 5 through 20 post-CHHI

  2. Anti-Na-GST-1 IgG antibody response [ Time Frame: 14 days after each vaccination, and approximately 1, 2, 4, 6, 7, 8 and 10 months after the third dose ]
    Anti-Na-GST-1 IgG antibody response, by a qualified indirect enzyme-linked immunosorbent assay (ELISA) at approximately 14 days after each vaccination, and approximately 1, 2, 4, 6, 7, 8 and 10 months after the third dose

  3. Anti-Na-GST-1 IgG antibody affinity [ Time Frame: 14 days after each vaccination, and approximately 1, 2, 4, 6, 7, 8 and 10 months after the third dose ]
    Affinity of the antibody interactions with recombinant Na-GST-1 antigen at approximately 14 days after each vaccination, and approximately 1, 2, 4, 6, 7, 8 and 10 months after the third dose.

  4. Memory B cells specific for Na-GST-1 [ Time Frame: 7 and 14 days following each vaccination; on day of CHHI; and then 7 and 14 days, and 5, 7, 13, and 20 weeks post-CHHI ]
    Production of memory B cells specific for Na-GST-1 on days of vaccination; approximately 7 and 14 days following each vaccination; on day of CHHI; and then 7 and 14 days, and 5, 7, 13, and 20 weeks post-CHHI.

  5. Innate immune responses [ Time Frame: Approximately 7 and 14 days following each vaccination; on day of CHHI; and then 7 and 14 days, and 5, 7, 13, and 20 weeks post-CHHI ]
    Innate immune responses on days of vaccination approximately 7 and 14 days following each vaccination; on day of CHHI; and then 7 and 14 days, and 5, 7, 13, and 20 weeks post-CHHI



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Males and non-pregnant females between 18 and 45 years, inclusive.
  2. Good general health as determined by means of the screening procedures1.
  3. Available for the duration of individual subject study participation (14 months).
  4. Willingness to participate in the study as evidenced by signing the informed consent document.
  5. Able to understand and comply with planned study procedures.

Exclusion Criteria:

  1. Pregnancy as determined by a positive urine human choriogonadotropin (hCG) test (if female).
  2. Subject unwilling to use effective contraception for a minimum of 30 days prior to vaccination and up until documentation of clearance of hookworm infection post-CHHI (if female and not surgically sterile, abstinent from intercourse with a male partner, in a monogamous relationship with a vasectomized partner, at least 2 years post-menopausal, or determined otherwise by medical evaluation to be sterile).
  3. Currently lactating and breast-feeding or plans to breastfeed at any given time from the first study vaccination until clearance of hookworm infection post-CHHI (if female).
  4. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, gastrointestinal, diabetes, or renal disease by history, physical examination, and/or laboratory studies.
  5. Has a diagnosis of schizophrenia, bipolar disease or other major psychiatric condition that would make compliance with study visits/procedures difficult (e.g., subject with psychoses or history of suicide attempt or gesture in the 3 years before study entry, ongoing risk for suicide).
  6. Known or suspected immunodeficiency or immunosuppression as a result of an underlying illness or treatment (causes for immunosuppression may include, but are not limited to, poorly-controlled diabetes mellitus, chronic liver disease, renal insufficiency, active neoplastic disease or a history of hematologic malignancy, connective tissue disease, organ transplant).
  7. Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25-times the upper reference limit).
  8. Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or urine dipstick testing positive for glucose or more than trace protein).
  9. Laboratory evidence of hematologic disease (hemoglobin <11.1 g/dl [females] or <12.5 g/dl [males]; absolute leukocyte count <3400/mm3 or >10.8 x 103/mm3; absolute eosinophil count <500/mm3; or platelet count <140,000/mm3).
  10. Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.
  11. Planned participation in another investigational vaccine or drug trial within 30 days of starting this study or until the last study visit (this may include other licensed or unlicensed vaccines, drugs, biologics, devices, blood products, or medications).
  12. Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 24 months.
  13. Positive fecal occult blood test at screening.
  14. Infection with a pathogenic intestinal helminth as determined by stool examination for ova and parasites at screening.
  15. History of iron deficiency anemia or laboratory evidence of iron deficiency (serum ferritin concentration below the lower reference limit).
  16. History of hypoalbuminemia.
  17. History of a severe allergic reaction or anaphylaxis.
  18. Severe asthma as defined by the need for daily use of inhalers, or emergency clinic visit or hospitalization within 6 months of the volunteer's expected first vaccination in the study.
  19. Positive test for hepatitis B surface antigen (HBsAg).
  20. Positive confirmatory test for HIV infection.
  21. Positive confirmatory test for hepatitis C virus (HCV) infection.
  22. Using or intends to continue using oral or parenteral corticosteroids, high-dose inhaled corticosteroids (>800 μg/day of beclomethasone dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs within 30 days of the volunteer's expected first vaccination in this study or planned use during the study.
  23. Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to the volunteer's expected first vaccination in the study.
  24. Receipt of immunoglobin or other blood products (with exception of Rho D immunoglobulin) within 90 days of the planned first study vaccination.
  25. Known allergy to albendazole, amphotericin B or gentamicin.
  26. History of previous infection with hookworm or continuous residence for more than 6 months in a community where hookworm is endemic.
  27. Current or past scars, tattoos, or other disruptions of skin integrity at the intended site of larval application.
  28. Previous receipt of the Na-GST-1/Alhydrogel® hookworm vaccine.
  29. History of a surgical splenectomy.
  30. Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosis, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia; or laboratory evidence of possible autoimmune disease determined by a positive anti-dsDNA titer, positive rheumatoid factor, and/or proteinuria (greater than trace protein on urine dipstick testing).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03172975


Contacts
Layout table for location contacts
Contact: Doreen Campbell, MSc 202-994-8976 hookworm@gwu.edu

Locations
Layout table for location information
United States, District of Columbia
George Washington University Recruiting
Washington, District of Columbia, United States, 20037
Contact: Doreen Campbell, MSc    202-994-8976    hookworm@gwu.edu   
Sponsors and Collaborators
Baylor College of Medicine
George Washington University
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Principal Investigator: David Diemert, MD George Washington University

Layout table for additonal information
Responsible Party: Maria Elena Bottazzi PhD, Principal Investigator, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT03172975     History of Changes
Other Study ID Numbers: 16-0116
U01AI129789 ( U.S. NIH Grant/Contract )
First Posted: June 1, 2017    Key Record Dates
Last Update Posted: July 18, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Maria Elena Bottazzi PhD, Baylor College of Medicine:
Controlled infection
Na-GST-1
Hookworm vaccine

Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Hookworm Infections
Ancylostomiasis
Strongylida Infections
Secernentea Infections
Nematode Infections
Helminthiasis
Parasitic Diseases
Albendazole
Aluminum Hydroxide
Anthelmintics
Antiparasitic Agents
Anti-Infective Agents
Anticestodal Agents
Antiplatyhelmintic Agents
Antiprotozoal Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antacids
Gastrointestinal Agents